Stefan M. Pulst, MD, Dr med, Editor, Nicholas Elwood Johnson, MD, Deputy Editor, Massimo Pandolfo, MD, FAAN, Raymond P. Roos, MD, FAAN and Jeffery M. Vance, MD, PhD, Associate Editors

2017 Year in Review and Message from the Editors to Our Reviewers

Neurol Genet February 2018 vol. 4 no. 1 e221. doi:10.1212/NXG.0000000000000221

The February issue of *Neurology® Genetics* again starts off with a review of articles that our editors found interesting in *Neurology: Genetics* and other journals over the course of 2017. It is a collection of articles from different walks of the genetics field, introduced with a brief commentary that should encourage the reader to delve further into the details of the topic.

Next-generation sequencing is revolutionizing identification of novel disease genes and patient diagnosis. Ribonuclease H1 (RNASEH1) digests the RNA present in RNA:DNA hybrids and is present in the nucleus and mitochondria. Bugiardi et al.¹ screened genomic DNAs from 74 probands with multiple deletions/depletion in muscle mtDNA and mendelian progressive external ophthalmoplegia (PEO). They identified 3 pedigrees of Indian ancestry with homozygous or compound heterozygous mutations. In addition to PEO, half of the patients had cerebellar ataxia and dysphagia. In the authors' cohort, RNASEH1 mutations represented the 4th most common cause of adult-onset PEO with multiple mtDNA deletions after POLG, RRM2B, and TWN.

Ahrens-Nicklas et al.² identified a mutation of the ATAD1 gene (p.E276X), encoding the AMPA receptor, as the etiology of a devastating neurologic disorder characterized by hypertonia, seizures, and death in a consanguineous family. This mutation was found to be associated with hyperactivity of the AMPA receptor. The authors designed used perampanel, an AMPA receptor antagonist, as a targeted therapeutic approach. They showed that perampanel therapy reversed the phenotype of ATAD1 knockout mice and improved hypertonicity and resolved seizures in patients. This is a good example of precision therapeutics applied to a human monogenic disorder.

As we are increasingly overwhelmed with DNA sequence data, computational solutions seem likely to be in the neurologist's future. This article explores 1 possibility to examine time-sensitive data, i.e., whole-genome DNA sequence (WGS) and RNA sequence from a glioblastoma patient's tumor.³ The WGS results were also compared with a targeted cancer panel of known variants. For the WGS/RNA-sequence data, the authors compared human annotation by a team of bioinformatic cancer experts vs a supercomputer to identify actionable variants. Both the human and supercomputer found more actionable variants than the targeted panel, reflecting the higher sensitivity of WGS/RNA sequence. Comparing the results of the 2 WGS analyses, the authors state that the supercomputer and the human annotation had comparable results, although the human annotation found more changes. But while the human annotation took 150 hours, the supercomputer took 10 minutes. The future seems pretty clear.

MORE ONLINE

🔗 **Editor Summary**
NPub.org/NG/edsum

From the Department of Neurology (S.M.P., N.E.J.), University of Utah, Salt Lake City; Hôpital Erasme (M.P.), Université Libre de Bruxelles, Belgium; University of Chicago Medical Center (R.P.R.); and University of Miami (J.M.V.), Coral Gables, FL.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

The importance of the microbiome was recognized in several models of human disease. With the application of next-generation or massively parallel DNA and RNA sequencing techniques, we now know the vast complexity and diversity of the microbiome of the gut. The interaction between the GI and the brain appears to influence inflammatory responses such as in MS and may have direct involvement in the rise of neurodegenerative conditions. Sampson et al.⁴ present evidence that the gut microbiome can directly affect the motor deficits, activation of microglia, and alpha-synuclein pathology in the brains of a Parkinson disease mouse model. They started with a PD mouse model that overexpresses alpha-synuclein, which had a “normal” mouse microbiome. This mouse model normally displays progressive motor deficits. Raising the same mouse strain in a germ-free environment, thus greatly decreasing their gut microbiome, reduced these deficits and pathologic changes in the mouse brain. Finally, adding back the microbiome of patients with Parkinson disease enhanced the motor deficits symptoms in the mice while the microbiome of non-PD patients had no appreciable effect. This interaction will become increasingly important in the care of neurologic patients as we move into the future.

Cerebral cavernous malformations (CCMs) are a cause of stroke and seizures with no effective medical therapy. CCMs arise from a loss of function in 3 genes that encode components of an adaptor complex that negatively regulates MEKK3–KLF2/4 signaling in brain endothelial cells. This article identified toll-like receptor 4 (TLR4) and the gut microbiome as critical stimulants of CCM formation.⁵ TLR4 activation by Gram-negative bacteria accelerated CCM formation, and blockade of TLR4 signaling prevented CCM formation in mice. Germ-free mice were protected from CCM formation, and antibiotics permanently altered CCM susceptibility in mice. These studies identify unexpected roles of the microbiome and innate immune signaling in the pathogenesis of a cerebrovascular disease that is inherited, as well as strategies for its treatment.

Novel therapies made significant advances in 2017. Potter et al.⁶ demonstrated significant advances in the treatment of dysferlinopathies using overlapping gene therapy vectors in a mouse model. In this study, they used dual vector dysferlin cassettes designed to capture either the 5′ or 3′ portion of the dysferlin cassette, with a 1-kb overlap for recombination. In a dysferlin knockout mouse model, the dual vectors were injected IV. Mice demonstrated improved myopathic features. The vectors were then shown to be safe in a rhesus macaque model. This study provides an important step in the development of gene therapies for muscular dystrophies, and we expect to see these promising therapies enter clinical trials shortly. More importantly, the study provides a proof of concept that dual vectors may be used when genes are too large for a single vector. This has important implications for gene therapy as a field.

Spinal muscular atrophy type 1 (SMA1) is a devastating disease resulting in death or the need for mechanical ventilation by 2 years of age. Affected infants never reach motor

milestones like independent sitting. The disease is caused by insufficient levels of the survival motor neuron (SMN) protein because of deletions or other loss-of-function mutations in the SMN1 gene. Mendell et al.⁷ delivered an adeno-associated virus (AAV) serotype 9 carrying SMN complementary DNA encoding the missing SMN protein by IV infusion to 15 infants with SMN1. All 15 patients were alive and event-free at 20 months of age as compared to a rate of survival of 8% in a historical cohort. AAV9-based gene therapy resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Side effects were minor, mostly limited to a transient increase in transaminases that was attenuated by prednisone. This is a landmark study demonstrating the potential of systemically administered gene therapy to revolutionize the treatment of neurogenetic diseases and radically change their prognosis.

Another approach to SMN treatment was pursued by Finkel et al.⁸ The SMN2 gene also encodes an SMN protein; however, 90%–95% of the translated protein is truncated and nonfunctional as a result of aberrant splicing. Nusinersen is an antisense oligonucleotide (ASO) that corrects the aberrant splicing of SMN2 pre-mRNA, which results in more full-length SMN protein. This article reports the results of a phase 3 trial of repeated intrathecal doses of nusinersen in infants with SMA compared with a sham group with SMA. The trial was terminated early because an interim analysis showed significant efficacy of nusinersen vs sham with respect to improvements in motor function as well as survival without permanent assisted ventilation. The best results were seen in patients with the earliest treatment. This new treatment, which is not a cure, brings a number of new challenges to treating neurologists, including issues of costs, delivery, and uncertain efficacy of the treatment if given to older patients with SMA, prompting van der Ploeg to write *The New England Journal of Medicine* editorial “The dilemma of 2 innovative therapies for Spinal Muscular Atrophy.”⁹

ASOs were also tested in preclinical models of other neurodegenerative disorders. Cognitive decline in Alzheimer disease and primary tauopathies is correlated with deposition of tau in the CNS. DeVos et al.¹⁰ studied the effects of ASOs directed to human tau in a mouse model of tauopathy. They delivered an ASO via Alzet pumps to the lateral ventricle and showed that reducing total tau mRNA lessened tau pathology, prevented hippocampal volume loss, and reduced behavioral deficits. When injected into monkeys via lumbar puncture, ASOs showed wide CNS distribution and reduced the levels of tau protein. Reduction of tau in hippocampal tissue correlated with reduction in monkey CSF. These studies and several others in 2017 provide hope that ASO-based therapies may offer hope for changing the progression in patients with a number of neurodegenerative diseases.

We wish to acknowledge the individuals who have completed reviews for the journal over the course of 2017—your thoughtful comments are tremendously helpful and highly appreciated. We are also grateful for your cooperation in returning reviews in a timely manner. Please find the guidelines

for reviewing articles on the *Neurology: Genetics* website at <http://ng.neurology.org/submit/peerreview>. This page provides information on expectations of reviewers regarding confidentiality, timeliness, and reviewer conflicts of interest; it also provides instructions for formatting the comments to editors and authors to enable the most effective communication with authors.

Please email ngjournal@neurology.org if you are interested in completing more reviews for *Neurology: Genetics*, or if you have never reviewed for the journal but are interested in doing so. Include a description of your credentials and expertise in the areas in which you are qualified to review. We look forward to hearing from you!

Our 2017 reviewers are listed at the end of this article.

Jan O. Aasly	Ramon Diaz-Arrastia	Joanna C. Jen	Garth A. Nicholson	Salvatore Spina
Gyula Acsadi	Salvatore DiMauro	Jun-ichi Kira	Jan Novy	Pasquale Striano
Laura Addis	E. Ray Dorsey	Christopher J. Klein	Karen Nuytemans	S. H. Subramony
Satish Agadi	Maria Teresa Dotti	Christine Klein	Paul A. Nyquist	Oksana Suchowersky
Christopher D. Anderson	James J. Dowling	David S. Knopman	Kinji Ohno	Russell H. Swerdlow
Corrado I. Angelini	Marisela Dy	Bobby Koeleman	Laurie Ozelius	Robert W. Taylor
Arunkanth Ankala	Kevin C. Ess	Akio Koizumi	Francesc Palau	Helio A.G. Teive
Egbert Bakker	Denise Anne Figlewicz	Vladimir S. Kostic	Johanna M. Palmio	Mustafa Tekin
Emma L. Baple	Nicola Filippini	Michael C. Kruer	Massimo Pandolfo	Dominic Thyagarajan
A. James Barkovich	Brent L. Fogel	Wolfram S. Kunz	Pau Pastor	Peter Todd
Gary W. Beecham	Shinsuke Fujioka	Patrick Kwan	Haydeh Payami	Teiji Tominaga
Christian Beetz	Yoshiaki Furukawa	Anne Lampe	Jordi Perez-Tur	Antonio Toscano
Laurence A. Bindoff	Antonio Gambardella	Suzanne Lesage	Margaret A. Pericak-Vance	Bryan J. Traynor
Thomas D. Bird	Paul A. Garcia	Jun Li	Piero Perucca	Jaya Trivedi
Sylvia M. Boesch	Thomas Gasser	Pawel P. Piotr Liberski	Robert D. S. Pitceathly	Shoji Tsuji
Giorgio B. Boncoraglio	Aaron D. Gitler	Dick Lindhout	Cyril Pottier	Enza Maria Valente
Renato Borgatti	Cyril Goizet	Noralane Lindor	Wendy Herlihy Raskind	Marka van Blitterswijk
Felippe Borlot	Christopher M. Gomez	Robert Listernick	Benjamin B. Roa	Arn MJM van den Maagdenberg
Alfredo Brusco	Anthony J. Griswold	Hanns Lochmuller	Ekaterina A. Rogaeva	Marjo S. van der Knaap
Marianna Bugiani	Renzo Guerrini	Iscia Lopes-Cendes	Raymond P. Roos	Jeffery M. Vance
Cynthia Campen	Randi J. Hagerman	Charles Marques Lourenco	Andreas Roos	Adeline Vanderver
Valerio Carelli	Jonathan L. Haines	Alfons Macaya	Margaret Elizabeth Ross	Shakkottai G. Vikram
Michael J. Chao	Peter Hedera	Mika H. Martikainen	Guy A. Rouleau	Robert B. Weiss
Nicolas Chrestian	Michael K Hehir	Antoni Matilla Dueñas	Filippo M. Santorelli	David John Werring
Bruce H. Cohen	Ingo Helbig	Donald S. McCorquodale	Ulrike Schara	John R. Wherrett
Yvette Conley	David N. Herrmann	Niccolo E. Mencacci	Susanne A. Schneider	Michel Willemsen
Marie Coutelier	Andrew A Hicks	John J. Millichap	Ludger Schöls	George R. Wilmot
Holly N. Cukier	Joseph James Higgins	Margherita Milone	Daniel Scoles	Juliane Winkelmann
William T. Dauer	Rogier Q. Hintzen	Ghayda Mirzaa	William K. Scott	Lee-Jun C. Wong
Glyn Dawson	Henry Houlden	Hidehiro Mizusawa	Pavel J.V. Seeman	Daniel Woo
Antonio V. Delgado-Escueta	Yue Huang	Christopher Moertel	Perry B. Shieh	Massimo Zeviani
Han-Xiang Deng	Inna Hughes	Huw R. Morris	Neil A. Shneider	Zhaolan Zhou
Chantal Depondt	Peter Huppke	Benedetta Nacmias	Michael E. Shy	Stephan Zierz
	Kinya Ishikawa			Stephan Zuchner
	Floor Elisabeth Jansen			

Study funding

No targeted funding reported.

Disclosure

S.M. Pulst serves on the editorial boards of the *Journal of Cerebellum*, *NeuroMolecular Medicine*, *Experimental Neurology*, *Neurogenetics*, and *Nature Clinical Practice Neurology*; receives research support from the NIH and the National Ataxia Foundation; has served on the speakers' bureau of Athena Diagnostics; receives publishing royalties from Churchill

Livingston, AAN Press, Academic Press, and Oxford University Press; has received license fee payments from Cedars-Sinai Medical Center; holds multiple patents; and receives an honorarium from the AAN as the Editor of *Neurology: Genetics*. N.E. Johnson has served as Associate Editor for *Neurology: Genetics*; has consulted for AMO Pharma and AveXis; and has received research support from Ionis Pharmaceuticals, Biogen Idec, Valerion Therapeutics, Cytokinetics, Acceleron, National Institute of Neurological Disorders and Stroke (1K23NS091511-01), Muscular Dystrophy Association, and Myotonic

Dystrophy Foundation. M. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of *Acta Neurologica Belgica*, the *Orphanet Journal of Rare Diseases*, and as Associate Editor of *Neurology: Genetics*; holds patents and receives royalties for Direct molecular diagnosis of Friedreich ataxia; has consulted for Biomarin and UCB; and has received research support from Biomarin, Fonds National de la Recherche Scientifique, Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires. R.P. Roos serves on the editorial board of *Virology* and *MedLink*; conducts research supported by the NIH, the ALS Association, the Judith and Jean Pape Adams Charitable Foundation, the Ralph and Marian Falk Medical Research Trust Grant, and the Chicago Biomedical Consortium; and is a stockholder of Amgen, Merck, Ionis Pharmaceuticals, and Express Scripts. J. M. Vance has received funding for travel or speaker honoraria from the NETPR, Department of Defense, and NIH; serves on the editorial boards of the *American Journal of Neurodegenerative Diseases* and as Associate Editor of *Neurology: Genetics*; holds patents for method of detecting Charcot-Marie-Tooth disease type 2A, TRPC6 involved in glomerulonephritis, and methods for identifying an individual at increased risk of developing coronary artery disease; has received research support from the NIH/National Institute of Neurological Disorders and Stroke and the Hussman Foundation; and receives royalties

from Duke University. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

References

1. Bugiardi E, Poole O, Manole A, et al. Clinicopathologic and molecular spectrum of RNASEH1-related mitochondrial disease. *Neurol Genet* 2017;3:e149. doi: 10.1212/NXG.0000000000000149.
2. Ahrens-Nicklas R, Umanah G, Sondheimer N, et al. Precision therapy for a new disorder of AMPA receptor recycling due to mutations in ATAD1. *Neurol Genet* 2017;3:e130. doi: 10.1212/NXG.0000000000000130.
3. Wrzeszczynski K, Frank M, Koyama T, et al. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. *Neurol Genet* 2017;3:e164. doi: 10.1212/NXG.0000000000000164.
4. Sampson T, Debelius J, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. *Cell* 2016;167:1469–1480. doi: 10.1016/j.cell.2016.11.018.
5. Zhou Z, Tang A, Wong W, et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3–KLF2/4 signalling. *Nature* 2016;532:122–126. doi: 10.1038/nature17178.
6. Potter RA, Griffin DA, Sondergaard PC et al. Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. *Hum Gen Ther* 2017. doi: 10.1089/hum.2017.062.
7. Mendell J, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med* 2017;377:1713–1722. doi: 10.1056/NEJMoa1706198.
8. Finkel R, Mercuri E, Darras B, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *N Engl J Med* 2017;377:1723–1732. doi: 10.1056/NEJMoa170275.
9. Van der Ploeg A. The dilemma of two innovative therapies for spinal muscular atrophy. *N Engl J Med* 2017;377:1786–1787. doi: 10.1056/NEJMe1712106.
10. DeVos S, Miller R, Schoch K et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. *Sci Transl Med* 2017. doi: 10.1126/scitranslmed.aag0481.

Neurology[®] Genetics

2017 Year in Review and Message from the Editors to Our Reviewers

Stefan M. Pulst, Nicholas Elwood Johnson, Massimo Pandolfo, et al.

Neurol Genet 2018;4;

DOI 10.1212/NXG.0000000000000221

This information is current as of February 20, 2018

Updated Information & Services	including high resolution figures, can be found at: http://ng.neurology.org/content/4/1/e221.full.html
References	This article cites 8 articles, 3 of which you can access for free at: http://ng.neurology.org/content/4/1/e221.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Genetics http://ng.neurology.org/cgi/collection/all_genetics
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://ng.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://ng.neurology.org/misc/addir.xhtml#reprintsus

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.